GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

经过长达5年的法律斗争，GSK最终还是选择了和解。

近日，辉瑞宣布终止针对呼吸道合胞病毒（RSV）治疗药物sisunatovir的开发。根据10月7日ClinicalTrials.gov网站的更新，辉瑞已经停止了两项关于sisunatovir治疗RSV感染的临床研究。

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

智通财经获悉，葛兰素史克(GSK.US)周三宣布，该公司已同意支付高达22亿美元，以解决美国州法院提起的大多数诉讼，这些诉讼指控一种已停产的胃灼热药物Zantac会导致癌症。该公司说，与10家原告律师事务所达成的协议解决了约8万起案件，占美国全国州法 ...

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

该诉讼声称，Moderna用于将mRNA传递到细胞中的脂质纳米粒子侵犯了GSK的专利。根据GSK的说法，这些专利是Moderna疫苗产品所使用的mRNA技术的基础。GSK此前曾在同一法院对辉瑞制药公司和BioNTech提起类似诉讼，针对的是他们联合开发的COVID-19疫苗。

智通财经APP获悉，葛兰素史克(GSK.US)用于治疗一种常见鼻炎的实验性药物在两项后期试验中显示出积极的结果，这促进了这家英国制药商的研发管道。据了解，Depemokimab有助于减少患有慢性鼻窦炎伴鼻息肉患者的鼻塞和息肉大小，葛兰素史克表示，这是 ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...